What Stivarga Treats: Main Uses and Benefits

Stivarga (Regorafenib) is a systemic therapy used in the management of three specific advanced cancers that have become resistant to prior standard treatments. Its primary purpose is to address the challenges of disease when other options may have been exhausted.

The medication is commonly used to address conditions marked by increased physiological stress in adult patients. It is relevant for metastatic colorectal cancer (mCRC), advanced Gastrointestinal Stromal Tumors (GIST), and Hepatocellular Carcinoma (HCC), provided the disease has progressed following specific initial treatments.

The primary benefit addresses symptoms linked to organ-specific functional stress in these conditions. The use of Stivarga in this context contributes to supportive management across difficult symptomatic phases.

“The primary therapeutic purpose is to provide support that may help with disease management in this refractory state.”

The medication is generally considered a relevant option to address the challenges presented by the advanced condition, helping maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relevant for Symptom Clusters that Create Noticeable Physiological Strain

Who can and cannot use Stivarga?

The official eligibility profile for Stivarga (Regorafenib) is defined by regulatory agencies, focusing on age, organ function, and reproductive status. The medicine is approved only for adult patients; its safety and efficacy are not established and not recommended in the pediatric population (under 18).

---

Populations Prohibited from Use

Stivarga is absolutely contraindicated in women who are pregnant, due to the risk of fetal harm. Use is also prohibited in patients with a known hypersensitivity to regorafenib or any formulation component. Women who are breastfeeding must not use the medicine and should stop for two weeks following the final dose.

---

Restrictions and Conditional Use

Patients with severe hepatic impairment (Child-Pugh C) are not recommended to use the drug, as clinical data is lacking in this group. Use is permitted with caution in patients with moderate hepatic impairment (Child-Pugh B). Use is generally permitted for patients with mild to severe renal impairment, though use in end-stage renal disease requiring dialysis is not established. Both males and females of reproductive potential must use effective contraception during treatment and for two months afterward. Specific caution is required for patients with a recent history of certain severe cardiac events, as these populations were excluded from pivotal clinical studies.

Interactions with other medicines and products

Official regulatory documentation identifies important drug interactions for regorafenib, primarily due to its metabolism by liver enzymes and its effect on drug transporters. These interactions may result in increased toxicity or reduced effectiveness of regorafenib or the co-administered medication.

Interacting Product Category	Practical Regulatory Implication
Strong CYP3A4 Inducers (e.g., rifampin, St. John's Wort)	Avoid concomitant use, as these medicines decrease the concentration of regorafenib in the body, potentially leading to decreased efficacy.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice)	Avoid concomitant use, as these increase the concentration of regorafenib, potentially increasing the risk of toxicity.
BCRP Substrates (e.g., rosuvastatin)	Monitor closely for signs of toxicity to the co-administered drug, as regorafenib inhibits the Breast Cancer Resistance Protein (BCRP) transporter, increasing the substrate's exposure.
Anticoagulants (e.g., warfarin, phenprocoumon)	Monitor coagulation parameters (such as INR) more frequently in patients with conditions predisposing to bleeding, due to the increased risk of hemorrhage when combined with regorafenib.

Regorafenib is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme pathway. Because its active metabolites, M-2 and M-5, are also involved in transporter function (P-gp and BCRP inhibition), these drug and food interactions necessitate close monitoring or complete avoidance to maintain the intended pharmacological effect and safety profile. Official labeling mandates avoiding both strong inducers and strong inhibitors of the CYP3A4 system.

How Stivarga Works

Regorafenib is a Multi-kinase inhibitor that acts simultaneously across three core biological domains by intervening in pathological signaling pathways.

---

Targeting Tumor Blood Supply (Anti-Angiogenesis)

The drug's mechanism begins with the inhibition of VEGFR1, VEGFR2, VEGFR3, and TIE2 receptors. This action suppresses the signaling necessary for endothelial cells to divide and form new blood vessels, resulting in reduced vascularization and limiting the supply of nutrients and oxygen to the tumor mass.

---

Blocking Oncogenic Growth Signals (Anti-Proliferation)

Regorafenib directly targets and deactivates key kinases such as KIT, RET, and BRAF that drive uncontrolled cell division and survival in cancer cells. By inhibiting these pathways, the mechanism results in cancer cell cycle arrest and activation of pro-apoptotic signaling.

---

Modulating the Tumor Microenvironment

A final domain involves blocking receptors like PDGFR and CSF1R on the tumor's supportive cells and immune components. This modulation reduces structural support and growth factor supply from the surrounding tissue, contributing to reduced signaling for proliferation and growth.

Official Administration Guidelines for Stivarga (Regorafenib)

Stivarga is an oral medication provided as 40 mg film-coated tablets. The administration protocol is defined in specific cycles, doses, and consumption requirements.

The recommended standard daily dose is 160 mg (four tablets), taken once daily, following a precise schedule.

---

Dosage and Treatment Cycle

Regimen Component	Official Guideline
Route	Oral (Swallowed whole with water)
Dosing	160 mg (four 40 mg tablets)
Frequency	Once daily, at the same time each day
Cycle Pattern	21 days of treatment followed by 7 days off-therapy (a 28-day cycle)

---

Contextual Administration Rules

The official instructions emphasize specific constraints for proper intake:

The tablets must be taken after a low-fat meal, which is defined as containing less than 30% fat. Dose adjustments, if needed, are performed in controlled 40 mg steps (one tablet), with the lowest approved dose being 80 mg. If a dose is missed, it should be taken later on the same day as soon as it is remembered; the patient must not take two doses to compensate for a missed dose from the previous day. No dose adjustment is required for older adults or patients with mild renal or mild hepatic impairment. Treatment continues as long as a benefit is observed.

Research Evidence / Overview of Studies for Stivarga (Regorafenib)

Understanding the available research involves looking closely at the studies conducted for each specific condition and recognizing the limitations of the evidence gathered so far. Research on Stivarga has primarily involved randomized, placebo-controlled trials.

---

Evidence for Use in Metastatic Colorectal Cancer (mCRC)

Stivarga was studied for use in adult patients with mCRC whose disease had progressed despite having received all available standard systemic treatments. This research examined a heavily pre-treated population. A significant portion of the evidence is derived from large randomized, double-blind, placebo-controlled trials. These studies monitored outcomes such as Overall Survival (OS), a metric that measures the time from randomization to death, and progression-free survival (PFS), which measures the time until the disease began to worsen or death occurred. Findings describe patterns observed in the studies where measurements for OS and PFS were reported to be different between the group receiving regorafenib and the group receiving placebo. The results apply only to the populations studied.

---

Evidence for Use in Gastrointestinal Stromal Tumors (GIST)

Research for GIST was conducted in patients whose advanced disease had progressed after receiving two other specific treatments. The main study was a Phase 3, randomized, placebo-controlled trial. The pivotal trial reported measurements related to progression or death that were observed to differ between the groups. The study allowed many patients in the placebo group to cross over to the regorafenib group once their disease progressed. Because of this crossover feature, the data show patterns related to overall survival (OS) that are considered less definitive than the data for progression-free survival.

---

Evidence for Use in Hepatocellular Carcinoma (HCC)

The evidence for this use is based on a randomized, double-blind, placebo-controlled trial. This trial was evaluated in patients who had Child-Pugh class A liver function. The primary outcome research examined was overall survival (OS). The research highlights changes measured during the study period that indicated differences in OS and PFS between the regorafenib and placebo groups. The results apply only to the populations studied.

---

Evidence in Specific Patient Groups and Key Areas of Uncertainty

The main trials included older adult patients, and some subgroup analyses explored whether the patterns observed were consistent across different age groups. Findings indicate that the patterns were observed in older adults as well, but certainty remains low for patients at the extreme end. For liver impairment, the data for outcomes in patients with moderate or severe liver dysfunction are not established by the main research. Research is still exploring the best order of use compared to other treatments, and data for certain groups remain insufficient. Limited information for long-term outcomes means that patterns over multiple years are not as well-characterized.

Common questions about Stivarga (FAQ)

Q: How quickly do patients usually experience side effects after starting Stivarga?

A: According to official product information, certain side effects tend to appear early in treatment. For instance, high blood pressure (Hypertension) and Hand-Foot Skin Reaction (HFSR) are often reported during the first 28-day cycle. Serious effects on the liver typically occur within the first two months of beginning the medicine.

Q: Are there any specific supplements or vitamins that should not be taken with Stivarga?

A: Regulatory documents caution against combining this medicine with certain products that affect liver enzymes. Specifically, the strong CYP3A4 inducer known as St. John’s Wort is subject to a regulatory caution for avoidance as it may reduce the concentration of the medicine and decrease its intended effect.

Q: What are the key signs of possible liver problems described in the official safety information?

A: Official patient information details observable signs of potential liver problems. These documented symptoms include pain or tenderness in the upper stomach area, yellowing of the skin or eyes, dark urine, or pale-colored stools. Additional symptoms documented include loss of appetite, nausea, or vomiting.

Q: Do official documents mention any effects of Stivarga on fertility?

A: Official warnings address the potential risk to reproductive health. Based on evidence from animal studies, this medicine may impair the function of reproductive organs. For this reason, regulatory guidance specifies the need for effective contraception during treatment and for a period of two months after the last dose for individuals of reproductive potential.

Q: What are the typical non-directive reasons for interrupting or discontinuing Stivarga treatment?

A: Regulatory guidance outlines specific medical conditions that may require interrupting or stopping the medicine. These non-directive reasons include the development of uncontrolled high blood pressure, severe or recurrent Hand-Foot Skin Reaction, or significant changes in liver function tests. Permanent discontinuation may be required for severe events such as gastrointestinal perforation or hemorrhage.

Q: How is the drug Stivarga physically supplied or packaged by the pharmacy?

A: The medicine is supplied as a distinct, film-coated tablet. According to the product monograph, the tablets are 40 mg, oval-shaped, and light pink in color. They are marked with the word 'BAYER' on one side and the number '40' on the reverse side.

Q: Is it normal to have mild gastrointestinal upset, like nausea, when first starting Stivarga?

A: Official clinical trial data reports that gastrointestinal upset is common. Nausea was a documented adverse event, occurring in 14% of patients studied. Other very common effects in the digestive system include diarrhea and inflammation of the mouth (oral mucositis).

Q: Does Stivarga have any described effects on the body's immune system function?

A: Official regulatory reports indicate a higher rate of infection in patients taking this medicine. Clinical trial data showed an increased incidence of various infections in patients receiving this treatment compared to those on placebo. This finding reflects the classification of infection as a serious adverse reaction.

Q: Can taking Stivarga cause hair thinning or noticeable hair loss?

A: Yes, hair changes are a documented adverse reaction. Official clinical trial data indicates that alopecia, which is the loss or thinning of hair on the scalp or body, occurred in 7% of patients studied.

Q: What kind of monitoring tests are required when a person is using Stivarga?

A: Official guidelines mandate specific monitoring during treatment. The patient's liver function must be checked before starting the drug, every two weeks for the first two months, and then monthly thereafter. Additionally, blood pressure should be checked regularly during the course of treatment.

Q: Does Stivarga interact with common over-the-counter pain medications like ibuprofen?

A: Regulatory safety warnings address interactions with anti-inflammatory drugs. Official information states that the use of anti-inflammatory drugs, such as ibuprofen or aspirin, may increase the chance of bleeding. Regulatory information describes the need for patient consultation with a healthcare professional regarding the use of these medications.

Q: Why is Stivarga prescribed in a pulsed or cycling regimen?

A: The 21-day on and 7-day off cycle was established for managing safety. This pulsed schedule was used in clinical trials to allow for the recovery from common adverse events that often require a break in the treatment. The cycle aims to help patients manage the side effects while continuing the therapy.

Q: Does Stivarga cause changes in a patient's sense of taste or smell?

A: Official documents confirm that taste changes are a documented side effect. Clinical trial data reported that taste alteration (known as dysgeusia) occurred in 7% of patients. Changes in taste are therefore recognized as a possible effect of the medicine.

Q: What is the difference between Stivarga (regorafenib) and Sorafenib (Nexavar)?

A: Both medicines are classified as multi-kinase inhibitors, but they are not identical. Official research indicates that Stivarga was studied and demonstrated clinical benefit in patients with liver cancer (HCC) who had already progressed following treatment with sorafenib. This finding highlights that the drug offers an option for patients who have experienced disease progression on prior therapies, including sorafenib.

How to Store and Dispose of Stivarga (Regorafenib)

Stivarga tablets must be stored at room temperature, specifically between 68 F to 77 F (20 C to 25 C). The medication must be kept in its original bottle, which should remain tightly closed. The desiccant inside the container must not be removed, and the tablets must not be placed into a pillbox.

Stability and Child Safety

For stability, any unused tablets must be safely discarded 7 weeks after the bottle is first opened. All medication must be stored out of the sight and reach of children.

Disposal

Official instructions prohibit disposing of Stivarga by flushing it down a toilet or throwing it into household trash. Unused or expired medication must be handled according to local regulations for cytotoxic and hazardous pharmaceutical waste, often through a medicine take-back program.